SCHEMBL1320792

SCHEMBL1320792

CCOC(=O)CNC1CCCCC1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.56
POLB P06746 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.50
THRB P10828 1/20 0.50
ATM Q13315 1/20 0.50
ALDH1A1 P00352 3/20 0.49
GAA P10253 2/20 0.45
MGAM O43451 1/20 0.45
SI P14410 1/20 0.45
MGAM2 Q2M2H8 1/20 0.45
EPHX2 P34913 2/20 0.45
HTT P42858 1/20 0.43
HPGD P15428 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 1/20 0.41
TP53 P04637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
EPHX1 P07099 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7326792 1.00 KDM4E (0.56) KDM4EPOLBL3MBTL1THRBATM
SCHEMBL7327410 1.00 KDM4E (0.56) KDM4EPOLBL3MBTL1THRBATM
Hydrochloric Acid SCHEMBL7331359 0.98 KDM4E (0.55) KDM4EPOLBL3MBTL1THRBATM
Hydrochloric Acid SCHEMBL7333958 0.98 KDM4E (0.55) KDM4EPOLBL3MBTL1THRBATM
Hydrochloric Acid SCHEMBL3742446 0.98 KDM4E (0.55) KDM4EPOLBL3MBTL1THRBATM
SCHEMBL7324398 0.98 KDM4E (0.54) KDM4EPOLBL3MBTL1THRBATM
Hydrochloric Acid SCHEMBL4274616 0.96 KDM4E (0.52) KDM4EPOLBL3MBTL1THRBATM
SCHEMBL11119817 0.94 KDM4E (0.50) KDM4EPOLBL3MBTL1THRBATM
Methylene Chloride SCHEMBL8889979 0.93 KDM4E (0.51) KDM4EPOLBL3MBTL1THRBATM
Hydrochloric Acid SCHEMBL11119814 0.93 KDM4E (0.49) KDM4EPOLBL3MBTL1THRBATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230065740-A1 CYCLIN-DEPENDENT KINASE INHIBITORS SPV THERAPEUTICS INC. 2023-03-02 US disclosed
WO-2022133083-A1 COMPOUNDS USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES, INC. (US) 2022-06-23 WO disclosed
WO-2020140054-A1 CYCLIN-DEPENDENT KINASE INHIBITORS SPV THERAPEUTICS INC. (US) 2020-07-02 WO disclosed
US-9487494-B2 Cyclic hydrocarbon compounds for the treatment of diseases LEO PHARMA A/S (DK) 2016-11-08 US disclosed
CN-101970394-B Novel cyclic hydrocarbon compounds for the treatment of diseases LEO PHARMA AS 2015-05-27 CN disclosed
CN-101090977-B Tripeptide and tetrapeptide thioethers TELIK INC 2013-04-10 CN disclosed
US-8058269-B2 rac-6-chloro-3-(3-chloro-benzyl)-3-(3-isopropoxy-phenylamino)-1,3-dihydro-indol-2-one; murine double minute (MDM2 ) oncogene inhibitor; feedback control loop of p53 mutant cells; inhibit the interaction between p53 and MDM2 proteins HOFFMAN-LA ROCHE INC. (US) 2011-11-15 US disclosed
US-8058269-B2 rac-6-chloro-3-(3-chloro-benzyl)-3-(3-isopropoxy-phenylamino)-1,3-dihydro-indol-2-one; murine double minute (MDM2 ) oncogene inhibitor; feedback control loop of p53 mutant cells; inhibit the interaction between p53 and MDM2 proteins HOFFMAN-LA ROCHE INC. (US) 2011-11-15 US disclosed
US-8058269-B2 rac-6-chloro-3-(3-chloro-benzyl)-3-(3-isopropoxy-phenylamino)-1,3-dihydro-indol-2-one; murine double minute (MDM2 ) oncogene inhibitor; feedback control loop of p53 mutant cells; inhibit the interaction between p53 and MDM2 proteins HOFFMAN-LA ROCHE INC. (US) 2011-11-15 US disclosed
CN-101970394-A Novel cyclic hydrocarbon compounds for the treatment of diseases LEO PHARMA AS 2011-02-09 CN disclosed
CN-1143964-A Pyrrolopyridazine derivative SANKYO CO (JP) 1997-02-26 CN disclosed
US-5578594-A ANTICOAGULANTS HOFFMANN-LA ROCHE INC. (US) 1996-11-26 US disclosed
EP-0742218-A1 PYRROLOPYRIDAZINE DERIVATIVE SANKYO COMPANY LIMITED (JP) 1996-11-13 EP disclosed
US-5405854-A Anticoagulants HOFFMANN-LA ROCHE INC. (US) 1995-04-11 US disclosed
EP-0640594-A1 Hydantoin derivative as metalloprotease inhibitor FUJIREBIO INC. (JP) 1995-03-01 EP disclosed
CN-1076690-A SULFONAMIDOCARBOXAMIDES HOFFMANN LA ROCHE (CH) 1993-09-29 CN disclosed
EP-0057998-B1 ALICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1984-08-08 EP disclosed
US-4421693-A INSECTICIDES, MITICIDES OR NEMATOCIDES OTSUKA CHEMICAL CO., LTD. (JP) 1983-12-20 US disclosed
US-4413005-A 2,3-DIHYDRO-2,2-DIMETHYLBENZOFURAN-7-YL DERIVATIVES OTSUKA KAGAKU YAKUHIN KABUSHIKI KAISHA (JP) 1983-11-01 US disclosed
EP-0057998-A1 Alicyclic compounds, their production and use Takeda Chemical Industries, Ltd. (JP) 1982-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230065740-A1 CYCLIN-DEPENDENT KINASE INHIBITORS CDK2, CDK1, CCNK KDM4E 1234/4885POLB 679/4885L3MBTL1 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.